A5041718282- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
- Epilepsy research and treatment
- Endometriosis Research and Treatment
- COVID-19 Clinical Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Pelvic floor disorders treatments
- Pharmaceutical studies and practices
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- Sexual function and dysfunction studies
- Virus-based gene therapy research
- Bone health and treatments
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Pharmacological Effects and Toxicity Studies
Emory University
2022-2025
Winship Cancer Institute
2023-2025
Emory Healthcare
2019-2022
Methodist University Hospital
2019
University of Tennessee at Knoxville
2019
American University of Integrative Sciences
2019
ABSTRACT Brentuximab vedotin (BV) is a drug that has improved outcomes in classical Hodgkin lymphoma (cHL). However, its safety and efficacy patients living with HIV who present severe liver failure life‐threating cytopenias unclear. Here, we describe the case of woman diagnosed cHL how she recovered from hemoglobin nadir 24 g/L despite declining transfusion support bilirubin peak 417.24 µmol/L, eventually achieving complete response BV‐based therapy. Studies are needed to determine BV...
Aim: More than half of patients with breast, lung, or prostate cancer who have bone metastases evidence skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator nuclear factor kappa-B ligand (RANKL) on osteoblasts their precursors. The United States Food Drug Administration (FDA)-approved dose denosumab 120 mg every 4 weeks; however, other schedules been used in practice for patient convenience. Evidence the safety...
Shah, Samarth P. PharmD, BCPS; Abousaud, Aseala PharmD; Nair, Reshma R.; Bergeron, Jaclyn MD; Cutshall, B. Tate BCPS Author Information
e14713 Background: Immune checkpoint inhibitor (ICI) therapy (pembrolizumab monotherapy and pembrolizumab combined with platinum-based chemotherapy) is recommended as first line for patients PD-L1 positive advanced or metastatic non-small cell lung cancer (NSCLC) without actionable biomarkers due to incredible improvements in overall survival (OS). Despite this, 15-20% of do not respond ICI NSCLC. This study examines the effect body composition features, via analytic morphomics, conjunction...